UK surgical sealant film company & Medilink member Tissuemed Ltd. has announced the
publication of a new clinical paper in World Neurosurgery relating to
its self-adhesive dural sealant film products.
Authored by Dr Paolo Ferroli, Professor Giovanni Broggi and co-workers at the Carlo Besta Institute, Milan,
this is a single centre retrospective study detailing 119 patients who
underwent elective neurosurgery. All patients received TissuePatchDural
to reinforce dural closure following identification of a CSF leak after
routine microsuture closure.
This was a mixed population of patients including 22 assessed as
being high risk for reasons including previous surgery, radiotherapy,
long term corticosteroid use and hydrocephalus. Supratentorial,
Infratentorial and Spinal patients were also included. Overall CSF leaks
were detected in 11 of the 119 patients (9.2%), all occurring within
two weeks of surgery. Patients were additionally assessed at 2 and 6
months following treatment and none were found to be suffering CSF
leakage.In the 22 patients considered high risk there was a higher
(36.3%) percentage of CSF leaks, compared to a 3.1% leak rate in 97
cases without additional risk. All leaks were treated conservatively
and no patient required readmission or repeat surgery. In conclusion,
the authors commented "In our experience the product appears to be safe
and no adverse reaction was evident throughout the study. Results in
terms of CSF leak prevention are promising."
Dr David Mandley, Tissuemed's CEO,
commented: "This latest paper, the third in 12 months published by
European Neurosurgeons, represents the largest patient cohort receiving
TissuePatchDural to be investigated and reported to date. As we
approach four years since the launch of TissuePatchDural I'm delighted
to have such positive clinical experience and published data from the
Carlo Besta Institute, a highly regarded and world renowned centre of
excellence in the field of neurosurgery."
About TissuePatchDural
The technology used in TissuePatch products is based on the in-situ
bonding of synthetic polymers to bodily tissues. The products are thin,
synthetic, films which bond covalently to amine groups on the surface
of internal tissues to provide a watertight seal. As such these films
are used as an adjunct to traditional suturing or stapling in a variety
of surgical procedures where achieving a secure closure is paramount.
The data also supports use of TissuePatchDural's sister product
ObexNeurofilm™, which is distributed by Medtronic's Neurosurgical
Technologies Division